Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare CVE:GPHNYSEMKT:IGCNYSE:OGNNASDAQ:PHAR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGPHGraphite OneC$0.76-1.3%C$0.84C$0.55▼C$1.07C$76.95M1.0271,101 shs84,773 shsIGCIGC Pharma$0.30-7.7%$0.30$0.25▼$0.55$23.91M1.48338,860 shs214,616 shsOGNOrganon & Co.$9.89+0.4%$9.94$8.01▼$23.10$2.56B0.583.45 million shs3.01 million shsPHARPharming Group$11.19+0.4%$9.82$6.65▼$12.61$757.86M0.026,134 shs1,914 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGPHGraphite One-1.30%-5.00%-3.80%-18.28%+7.04%IGCIGC Pharma0.00%-3.53%-1.63%-4.44%+30,099,900.00%OGNOrganon & Co.+0.21%-2.17%+9.84%-36.69%-51.42%PHARPharming Group+2.75%-3.24%+20.71%+27.03%+36.46%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationGPHGraphite OneN/AN/AN/AN/AN/AN/AN/AN/AIGCIGC Pharma1.5536 of 5 stars3.50.00.00.01.11.70.0OGNOrganon & Co.4.5733 of 5 stars3.32.01.73.71.73.31.9PHARPharming Group2.4433 of 5 stars3.53.00.00.03.20.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGPHGraphite One 0.00N/AN/AN/AIGCIGC Pharma 3.00Buy$3.881,187.38% UpsideOGNOrganon & Co. 2.50Moderate Buy$18.0082.08% UpsidePHARPharming Group 3.00Buy$30.00168.10% UpsideCurrent Analyst Ratings BreakdownLatest PHAR, OGN, GPH, and IGC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/22/2025OGNOrganon & Co.BNP ParibasSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/15/2025OGNOrganon & Co.Piper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$24.00 ➝ $18.005/5/2025OGNOrganon & Co.Morgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$15.00 ➝ $10.005/2/2025OGNOrganon & Co.Evercore ISISubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Inline4/9/2025OGNOrganon & Co.Morgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$16.00 ➝ $15.003/20/2025PHARPharming GroupHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$37.00 ➝ $37.00(Data available from 6/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGPHGraphite OneN/AN/AC$0.01 per share94.17C$0.44 per shareN/AIGCIGC Pharma$1.24M19.41N/AN/A$0.08 per share3.76OGNOrganon & Co.$6.40B0.40$4.94 per share2.00$1.83 per share5.40PHARPharming Group$297.20M2.56$0.07 per share150.28$3.25 per share3.44Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGPHGraphite One-C$4.90M-C$0.07N/A∞N/AN/A-10.96%-6.61%N/AIGCIGC Pharma-$13M-$0.11N/AN/AN/A-714.16%-122.44%-88.40%N/AOGNOrganon & Co.$864M$2.883.432.641.0311.92%227.43%7.34%8/5/2025 (Estimated)PHARPharming Group-$11.84M-$0.20N/A373.00N/A-4.14%-6.01%-3.23%7/30/2025 (Estimated)Latest PHAR, OGN, GPH, and IGC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025PHARPharming Group-$0.25-$0.22+$0.03-$0.22$67.74 million$79.09 million5/1/2025Q1 2025OGNOrganon & Co.$0.89$1.02+$0.13$0.33$1.53 billion$1.51 billionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthGPHGraphite OneN/AN/AN/AN/AN/AIGCIGC PharmaN/AN/AN/AN/AN/AOGNOrganon & Co.$0.080.81%N/A2.78%N/APHARPharming GroupN/AN/AN/AN/AN/ALatest PHAR, OGN, GPH, and IGC DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date5/2/2025OGNOrganon & Co.quarterly$0.020.8%5/12/20255/12/20256/12/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGPHGraphite One0.021.090.33IGCIGC Pharma0.021.150.98OGNOrganon & Co.16.491.671.15PHARPharming Group0.392.762.00Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGPHGraphite One0.07%IGCIGC Pharma3.87%OGNOrganon & Co.77.43%PHARPharming Group0.03%Insider OwnershipCompanyInsider OwnershipGPHGraphite One28.81%IGCIGC Pharma31.48%OGNOrganon & Co.1.96%PHARPharming Group2.07%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGPHGraphite One20101.25 millionN/ANot OptionableIGCIGC Pharma6179.69 million54.60 millionN/AOGNOrganon & Co.4,000259.96 million254.86 millionNot OptionablePHARPharming Group28068.03 million66.62 millionNot OptionablePHAR, OGN, GPH, and IGC HeadlinesRecent News About These CompaniesPharming Group (NASDAQ:PHAR) Shares Down 3.2% - Here's WhyJune 18 at 2:18 PM | marketbeat.comPharming Group (NASDAQ:PHAR) Sees Strong Trading Volume - Here's What HappenedJune 17 at 12:43 PM | marketbeat.comPharming Group (NASDAQ:PHAR) Shares Gap Up - Time to Buy?June 16 at 12:52 PM | marketbeat.comShort Interest in Pharming Group (NASDAQ:PHAR) Expands By 169.2%June 13, 2025 | marketbeat.comEuropean Penny Stocks Under €200M Market Cap To WatchJune 13, 2025 | uk.finance.yahoo.comPharming Group (NASDAQ:PHAR) Trading 3.9% Higher - Here's What HappenedJune 12, 2025 | marketbeat.comPharming Group reports on results of the 2025 Annual General Meeting of ShareholdersJune 11, 2025 | finance.yahoo.comPharming Group Announces Key Board Appointments and Approvals at 2025 AGMJune 11, 2025 | tipranks.comPharming Group (NASDAQ:PHAR) Sees Large Volume Increase - Here's WhyJune 11, 2025 | marketbeat.comPharming Group (NASDAQ:PHAR) Shares Down 4.6% - Here's What HappenedJune 10, 2025 | marketbeat.comPharming Group (NASDAQ:PHAR) Stock Price Up 6.7% - Here's What HappenedJune 6, 2025 | marketbeat.comPharming Group (NASDAQ:PHAR) Shares Gap Down - Should You Sell?June 5, 2025 | marketbeat.comPharming Group (NASDAQ:PHAR) Shares Gap Up - Here's What HappenedJune 4, 2025 | marketbeat.comPharming Group (NASDAQ:PHAR) Reaches New 1-Year High - What's Next?June 3, 2025 | marketbeat.comPharming Group (NASDAQ:PHAR) Sees Large Decline in Short InterestJune 3, 2025 | marketbeat.comPharming Group (NASDAQ:PHAR) Stock Price Up 10.1% - Here's What HappenedMay 31, 2025 | marketbeat.comPharming Group to participate in June investor conferencesMay 28, 2025 | finance.yahoo.comPharming Group to participate in June investor conferences | PHARM Stock NewsMay 28, 2025 | gurufocus.comPharming Group First Quarter 2025 Earnings: US$0.022 loss per share (vs US$0.019 loss in 1Q 2024)May 10, 2025 | finance.yahoo.comPharming Group N.V. (PHAR) Q1 2025 Earnings Call TranscriptMay 9, 2025 | seekingalpha.comPharming Group N.V. 2025 Q1 - Results - Earnings Call PresentationMay 9, 2025 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Defense Stocks That Will Profit From a Golden DomeBy Chris Markoch | May 30, 2025View 3 Defense Stocks That Will Profit From a Golden DomeAnalysts Think These Stocks Could More Than Double in ValueBy Nathan Reiff | May 23, 2025View Analysts Think These Stocks Could More Than Double in ValueThese Are the Only 6 Stock Stocks in NVIDIA's 13F PortfolioBy Leo Miller | May 22, 2025View These Are the Only 6 Stock Stocks in NVIDIA's 13F PortfolioAnalysts Can't Get Enough of These Little-Known Biopharma StocksBy Nathan Reiff | June 12, 2025View Analysts Can't Get Enough of These Little-Known Biopharma StocksEli Lilly : A Breakout Biotech Powerhouse With Room to RunBy Jeffrey Neal Johnson | May 29, 2025View Eli Lilly : A Breakout Biotech Powerhouse With Room to RunPHAR, OGN, GPH, and IGC Company DescriptionsGraphite One CVE:GPHC$0.76 -0.01 (-1.30%) As of 06/18/2025 03:23 PM EasternGraphite One Inc. operates as mineral exploration company in the United States. The company holds interest in the Graphite Creek property that consists of 135 mining claims located on the Seward Peninsula, Alaska. The company was formerly known as Graphite One Resources Inc. and changed its name to Graphite One Inc. in February 2019. Graphite One Inc. was incorporated in 2006 and is headquartered in Vancouver, Canada.IGC Pharma NYSEMKT:IGC$0.30 -0.03 (-7.70%) Closing price 06/18/2025 03:58 PM EasternExtended Trading$0.30 0.00 (-0.33%) As of 06/18/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.IGC Pharma, Inc., a clinical stage pharmaceutical company, engages in developing treatments for Alzheimer's disease. The company's lead product is IGC-AD1, which is in a Phase 2B clinical trial as a treatment for agitation in dementia due to Alzheimer's; and TGR-63, IGC-1C, IGC-M3, and LMP in pre-clinical development. The company was formerly known as India Globalization Capital, Inc. and changed its name to IGC Pharma, Inc. in March 2023. The company was incorporated in 2005 and is headquartered in Potomac, Maryland.Organon & Co. NYSE:OGN$9.89 +0.04 (+0.37%) Closing price 06/18/2025 03:59 PM EasternExtended Trading$9.85 -0.04 (-0.41%) As of 06/18/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.Pharming Group NASDAQ:PHAR$11.19 +0.05 (+0.45%) Closing price 06/18/2025 03:57 PM EasternExtended Trading$10.27 -0.92 (-8.22%) As of 06/18/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Chime’s Smart IPO: Half the Valuation, Double the Strength Salesforce Raises Prices: 3 Reasons Its Stock Price Will Follow Tesla Bulls and Bears Collide: What Investors Should Know Qualcomm: A Technical Setup Is Emerging, and It's Bullish 330% Returns YTD: Is CoreWeave's Momentum Softening? Why Quantum Computing Inc. Is the Quiet Winner in Quantum Stocks 3 Catalysts in 7 Days: Archer's Growth Story Just Accelerated Microsoft-OpenAI Rift May Cap Stock Upside Potential Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
